IPR: National Policy, Patent Filings & Pharma Sovereignty

UPSC Mains PYQs

IPR & Evergreening (2019): In the context of the Intellectual Property Rights (IPR) regime, discuss the significance of Section 3(d) of the Indian Patents Act, 1970. Analyze the debate between multinational pharmaceutical companies and domestic generic manufacturers regarding evergreening of patents. (15 Marks, 250 Words)

📊 High-Yield Data & Statistical Fact Sheet

IPR & Innovation Metrics:
- Patent Scale: India registered a record 1,10,000+ patent applications in recent cycles, with the CGPDTM granting over 1,00,000 patents in a single year.
- Resident Leadership: Domestic (resident) filings represent 61.8% of the total patent applications, marking a shift from foreign dominance.
- GI Portfolio: India has registered over 643 Geographical Indications (GIs), protecting 11 Million rural artisans and growers.
- Processing Timeline: Average patent disposal time slashed from 72 months (2016) to 18-24 months (target: <12 months for startups).
- TKDL Security: Digitized 4.5 Lakh traditional formulations in 5 languages, blocking 250+ biopiracy patent attempts internationally.
- Pharma Price Gap (Section 3d): patented cancer drug Glivec costs ~₹1.2 Lakh/month; domestic generic equivalent under Section 3(d) costs ₹8,000 to ₹10,000/month.

Loading chart...

Loading chart...

1. NATIONAL IPR POLICY & ADMINISTRATIVE ACCELERATION

National IPR Policy ("Creative India; Innovative India"):
- Admin Integration: Brings all IP administration (Patents, Designs, Trademarks, GI, Copyrights) under the DPIIT (Ministry of Commerce) via the CGPDTM.
- Expedited Examination: Speeds up patent grants for startups, MSMEs, and female applicants to foster commercialization.
CIPAM (Cell for IPR Promotion and Management): Nodal agency under DPIIT tasked with increasing public IPR awareness across schools, universities, and industries.
Resident Patent Surge: Resident filings rising to 61.8% of total applications reflects growing domestic R&D capacity under the Atmanirbhar Bharat model.

Section 3(d) of the Patents Act, 1970:
- The Rule: Declares that minor modifications, new forms, or new uses of known substances are not patentable unless they demonstrate a significant enhancement in therapeutic efficacy.
- Anti-Evergreening Moat: Prevents multinational pharmaceutical companies from extending their 20-year patent monopoly through minor chemical changes (evergreening). Essential for sustaining India's generic drug industry.
Compulsory Licensing (Section 84): A sovereign mechanism under the WTO TRIPS agreement. Allows the government to permit domestic generic firms to manufacture patented drugs without the owner's consent during public health emergencies (e.g., Natco license for Bayer's Nexavar).

Traditional Knowledge Digital Library (TKDL): A digital database containing traditional medical knowledge (Ayurveda, Siddha, Unani, Yoga) translated into 5 international languages. Provides patent examiners worldwide with prior art to block biopiracy.
Geographical Indications (GI) Protection:
- Socioeconomic Impact: Protects community IPR for regional products (e.g., Darjeeling Tea, Basmati Rice, Kandhamal Haldi).
- Livelihood Shield: Prevents unauthorized imitation and boosts exports, supporting rural growers and craftspeople.

Notes updated up to March 2026. Sources: CGPDTM Annual Reports, DPIIT IPR Policy Briefs.